van Oosten BW - Search Results

1

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Killestein J, et al. Among authors: van oosten bw. Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074. Ann Neurol. 2010. PMID: 20661928

2

Response: Brain miliary enhancement.

Bot JCJ, Mazzai L, Hagenbeek RE, Ingala S, van Oosten B, Sanchez-Aliaga E, Barkhof F. Bot JCJ, et al. Neuroradiology. 2020 May;62(5):547. doi: 10.1007/s00234-020-02404-0. Epub 2020 Mar 25. Neuroradiology. 2020. PMID: 32215682 No abstract available.

3

Multiple sclerosis therapy. A practical guide.

van Oosten BW, Truyen L, Barkhof F, Polman CH. van Oosten BW, et al. Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005. Drugs. 1995. PMID: 7729328 Review.

4

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Adèr HJ, Barkhof F. Truyen L, et al. Among authors: van walderveen ma, van oosten bw, van waesberghe jh. Neurology. 1996 Dec;47(6):1469-76. doi: 10.1212/wnl.47.6.1469. Neurology. 1996. PMID: 8960729

5

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. van Oosten BW, et al. Neurology. 1996 Dec;47(6):1531-4. doi: 10.1212/wnl.47.6.1531. Neurology. 1996. PMID: 8960740

6

A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.

van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, Hartung HP, Adèr HJ, Polman CH. van Oosten BW, et al. Among authors: van lier ra. J Neuroimmunol. 1996 May;66(1-2):49-55. doi: 10.1016/0165-5728(96)00019-7. J Neuroimmunol. 1996. PMID: 8964913 Clinical Trial.

7

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

Rep MH, van Oosten BW, Roos MT, Adèr HJ, Polman CH, van Lier RA. Rep MH, et al. Among authors: van lier ra, van oosten bw. J Clin Invest. 1997 May 1;99(9):2225-31. doi: 10.1172/JCI119396. J Clin Invest. 1997. PMID: 9151795 Free PMC article. Clinical Trial.

8

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. van Oosten BW, et al. Neurology. 1997 Aug;49(2):351-7. doi: 10.1212/wnl.49.2.351. Neurology. 1997. PMID: 9270561 Clinical Trial.

9

Interleukin-2 therapy does not exacerbate multiple sclerosis.

van Oosten BW, Uitdehaag BM, Barkhof F, Hartung HP, Wagstaff J, Polman CH. van Oosten BW, et al. Neurology. 1997 Aug;49(2):633-4. doi: 10.1212/wnl.49.2.633. Neurology. 1997. PMID: 9270618 No abstract available.

10

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

van Oosten BW, Lai M, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Hodgkinson S, Polman CH. van Oosten BW, et al. Mult Scler. 1996 Jul;1(6):339-42. doi: 10.1177/135245859600100611. Mult Scler. 1996. PMID: 9345413 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results